Essex Investment Management Co. LLC Has $2.92 Million Stock Position in SI-BONE, Inc. (NASDAQ:SIBN)

Essex Investment Management Co. LLC boosted its stake in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 24.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 208,160 shares of the company's stock after buying an additional 40,636 shares during the period. Essex Investment Management Co. LLC owned 0.50% of SI-BONE worth $2,918,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Impax Asset Management Group plc boosted its holdings in shares of SI-BONE by 41.3% in the third quarter. Impax Asset Management Group plc now owns 758,521 shares of the company's stock valued at $10,604,000 after acquiring an additional 221,604 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in SI-BONE by 1.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 315,092 shares of the company's stock worth $4,405,000 after purchasing an additional 5,966 shares during the period. Champlain Investment Partners LLC boosted its stake in SI-BONE by 14.7% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company's stock valued at $39,145,000 after purchasing an additional 358,821 shares in the last quarter. Millrace Asset Group Inc. acquired a new position in shares of SI-BONE during the 3rd quarter valued at $1,056,000. Finally, FMR LLC raised its stake in shares of SI-BONE by 103.6% in the 3rd quarter. FMR LLC now owns 2,354 shares of the company's stock worth $33,000 after buying an additional 1,198 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company's stock.

Remove Ads

Insider Buying and Selling

In related news, CFO Anshul Maheshwari sold 5,304 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total transaction of $73,778.64. Following the completion of the sale, the chief financial officer now directly owns 189,319 shares in the company, valued at approximately $2,633,427.29. This trade represents a 2.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Anthony J. Recupero sold 3,670 shares of SI-BONE stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total value of $51,013.00. Following the sale, the insider now directly owns 222,814 shares of the company's stock, valued at approximately $3,097,114.60. The trade was a 1.62 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 9,311 shares of company stock worth $130,356. 3.90% of the stock is owned by company insiders.

SI-BONE Trading Down 0.3 %

SIBN traded down $0.04 during trading on Thursday, reaching $14.71. The company had a trading volume of 264,647 shares, compared to its average volume of 358,047. The firm's 50-day simple moving average is $16.51 and its 200 day simple moving average is $14.89. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The company has a market cap of $624.48 million, a price-to-earnings ratio of -15.99 and a beta of 1.17. SI-BONE, Inc. has a 12-month low of $11.70 and a 12-month high of $19.16.

SI-BONE (NASDAQ:SIBN - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $49.00 million during the quarter, compared to analysts' expectations of $48.87 million. Equities research analysts anticipate that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Needham & Company LLC raised their target price on SI-BONE from $20.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Truist Financial reaffirmed a "buy" rating and issued a $22.00 price objective (up previously from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 target price on shares of SI-BONE in a research note on Tuesday, February 25th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $24.50.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.